美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Biofrontera Inc Warrant

0.0624

-0.0006-0.95%

成交量：3,200.00

成交額：199.84

市值：66.57萬

市盈率：-0.03

高：0.0625

開：0.0625

低：0.0624

收：0.0630

52周最高：0.2770

52周最低：0.0251

股本：1,066.84萬

流通股本：1,066.84萬

量比：3.61

換手率：0.03%

股息：- -

股息率：- -

每股收益(TTM):-1.8444

淨資產收益率：-325.31%

總資產收益率：-35.18%

市淨率：0.04

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

Biofrontera Inc公布積極二期B階段結果支持Ameluz®光動力療法針對中重度痤瘡的進一步開發

Biofrontera Inc 預計於2026年第三季度提交四肢、頸部和軀幹適應症的補充新藥申請

Biofrontera Inc宣佈完成用於軀幹及四肢光化性角化病的Ameluz®一期藥代動力學研究數據庫鎖定

Biofrontera宣佈FDA受理Ameluz®光動力療法治療淺表基底細胞癌的補充新藥申請

Biofrontera公布Ameluz®光動力療法治療四肢、頸部和軀幹光化性角化病三期研究積極結果，達到主要終點

Biofrontera Inc宣佈兩項臨床研究數據庫鎖定，助力關鍵數據與監管里程碑達成

Biofrontera Inc. 完成 Ameluz® 和 Rhodoled® 的 FDA 批准轉移及相關知識產權組合的轉讓

Biofrontera Inc. 宣佈將 Xepi® 抗生素乳膏的許可出售給 Pelthos Therapeutics Inc.，最高可達 1000 萬美元

Biofrontera Inc宣佈Ameluz®(鹽酸氨基酮戊酸)外用凝膠10%光動力療法治療四肢、頸部和軀幹光化性角化病三期研究最後一名患者完成試驗

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BFRIW/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BFRIW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BFRIW\",,,,,undefined,":{"symbol":"BFRIW","market":"US","secType":"STK","nameCN":"Biofrontera Inc Warrant","latestPrice":0.0624,"timestamp":1773259200000,"preClose":0.063,"halted":0,"volume":3200,"delay":0,"changeRate":-0.009523809523809577,"floatShares":10668438,"shares":10668438,"eps":-1.8444,"marketStatus":"未開盤","change":-0.0006,"latestTime":"03-11 16:00:00 EDT","open":0.0625,"high":0.0625,"low":0.0624,"amount":199.84,"amplitude":0.001587,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.8444,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1773302400000},"marketStatusCode":0,"adr":0,"listingDate":1635480000000,"exchange":"NASDAQ","adjPreClose":0.063,"volumeRatio":3.60848},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BFRIW\",,,,,undefined,":{"symbol":"BFRIW","floatShares":10668438,"roa":"-35.18%","roe":"-325.31%","lyrEps":0,"volumeRatio":3.60848,"shares":10668438,"dividePrice":0,"high":0.0625,"amplitude":0.001587,"preClose":0.063,"low":0.0624,"week52Low":0.0251,"pbRate":"0.04","psRate":"0.02","week52High":0.277,"institutionHeld":0,"latestPrice":0.0624,"eps":-1.8444,"divideRate":0,"volume":3200,"delay":0,"ttmEps":-1.8444,"open":0.0625,"prevYearClose":0.09,"prevWeekClose":0.046,"prevMonthClose":0.0679,"prevQuarterClose":0.09,"fiveDayClose":0.066,"twentyDayClose":0.0634,"sixtyDayClose":0.07},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BFRIW\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BFRIW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BFRIW\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BFRIW\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1155586230","title":"Biofrontera Inc公布積極二期B階段結果 支持Ameluz®光動力療法針對中重度痤瘡的進一步開發","url":"https://stock-news.laohu8.com/highlight/detail?id=1155586230","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155586230?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 21:15","pubTimestamp":1773062116,"startTime":"0","endTime":"0","summary":"Biofrontera Inc宣布其Ameluz®光动力疗法在治疗中重度寻常型痤疮的二期B阶段临床试验中取得积极结果。该结果有力支持该疗法的后续研发推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BFRIW","BFRI","BK4007"],"gpt_icon":0},{"id":"1180429435","title":"Biofrontera Inc 預計於2026年第三季度提交四肢、頸部和軀幹適應症的補充新藥申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1180429435","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180429435?lang=zh_tw&edition=fundamental","pubTime":"2026-02-17 22:16","pubTimestamp":1771337802,"startTime":"0","endTime":"0","summary":"Biofrontera Inc 计划在2026年第三季度向监管机构提交一份补充新药申请（sNDA），该申请针对的是其在四肢、颈部和躯干方面的适应症扩展。此举标志着公司在拓展其产品应用范围方面迈出了重要一步，有望为相关患者群体提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BFRIW","BFRI","BK4007"],"gpt_icon":0},{"id":"1184834707","title":"Biofrontera Inc宣佈完成用於軀幹及四肢光化性角化病的Ameluz®一期藥代動力學研究數據庫鎖定","url":"https://stock-news.laohu8.com/highlight/detail?id=1184834707","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184834707?lang=zh_tw&edition=fundamental","pubTime":"2026-02-17 22:15","pubTimestamp":1771337729,"startTime":"0","endTime":"0","summary":"Biofrontera Inc（纳斯达克代码：BFRI）近日宣布，其针对躯干及四肢光化性角化病的Ameluz®药物一期药代动力学研究已完成数据库锁定。这一关键步骤标志着该临床试验数据收集阶段的正式结束，为后续的数据分析和结果评估奠定了坚实基础。公司表示，此项研究的推进将进一步丰富Ameluz®在皮肤疾病治疗领域的临床应用数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BFRIW","BK4007","BFRI"],"gpt_icon":0},{"id":"1161002689","title":"Biofrontera宣佈FDA受理Ameluz®光動力療法治療淺表基底細胞癌的補充新藥申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1161002689","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161002689?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 22:16","pubTimestamp":1770819389,"startTime":"0","endTime":"0","summary":"Biofrontera Inc（简称Biofrontera）近日宣布，美国食品药品监督管理局（FDA）已正式受理其针对Ameluz®光动力疗法（PDT）用于治疗浅表基底细胞癌（sBCC）的补充新药申请（sNDA）。这一重要进展标志着该药物在拓展适应症方面迈出了关键一步，为患者提供了潜在的新治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BFRI","BFRIW","BK4007"],"gpt_icon":0},{"id":"1179752893","title":"Biofrontera公布Ameluz®光動力療法治療四肢、頸部和軀幹光化性角化病三期研究積極結果，達到主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=1179752893","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179752893?lang=zh_tw&edition=fundamental","pubTime":"2026-02-09 22:16","pubTimestamp":1770646572,"startTime":"0","endTime":"0","summary":"Biofrontera Inc (NASDAQ: BFRI) 宣布，其用于治疗四肢、颈部和躯干光化性角化病的Ameluz®光动力疗法在三期临床研究中取得积极结果，成功达到了主要研究终点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BFRI","BFRIW","BK4007"],"gpt_icon":0},{"id":"1141539493","title":"Biofrontera Inc宣佈兩項臨床研究數據庫鎖定，助力關鍵數據與監管里程碑達成","url":"https://stock-news.laohu8.com/highlight/detail?id=1141539493","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141539493?lang=zh_tw&edition=fundamental","pubTime":"2026-01-08 21:50","pubTimestamp":1767880249,"startTime":"0","endTime":"0","summary":"Biofrontera Inc宣布，其两项临床研究已完成数据库锁定，此举将为关键数据的获取及后续监管里程碑的实现提供重要支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BFRI","BFRIW"],"gpt_icon":0},{"id":"1137380408","title":"Biofrontera Inc. 完成 Ameluz® 和 Rhodoled® 的 FDA 批准轉移及相關知識產權組合的轉讓","url":"https://stock-news.laohu8.com/highlight/detail?id=1137380408","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137380408?lang=zh_tw&edition=fundamental","pubTime":"2025-12-18 21:50","pubTimestamp":1766065819,"startTime":"0","endTime":"0","summary":"Biofrontera Inc. 完成 Ameluz® 和 Rhodoled® 的 FDA 批准转移及相关知识产权组合的转让","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BFRIW","BFRI"],"gpt_icon":0},{"id":"1160367010","title":"Biofrontera Inc. 宣佈將 Xepi® 抗生素乳膏的許可出售給 Pelthos Therapeutics Inc.，最高可達 1000 萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1160367010","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160367010?lang=zh_tw&edition=fundamental","pubTime":"2025-11-07 21:02","pubTimestamp":1762520543,"startTime":"0","endTime":"0","summary":"Biofrontera Inc. 宣布将 Xepi® 抗生素乳膏的许可出售给 Pelthos Therapeutics Inc.，最高可达 1000 万美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BFRIW","BFRI","BK4007"],"gpt_icon":0},{"id":"1185650039","title":"Biofrontera Inc宣佈Ameluz®(鹽酸氨基酮戊酸)外用凝膠10%光動力療法治療四肢、頸部和軀幹光化性角化病三期研究最後一名患者完成試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1185650039","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185650039?lang=zh_tw&edition=fundamental","pubTime":"2025-09-16 22:30","pubTimestamp":1758033054,"startTime":"0","endTime":"0","summary":"Biofrontera Inc近日宣布，其针对Ameluz®(盐酸氨基酮戊酸)外用凝胶10%光动力疗法的三期临床研究已完成最后一名患者的试验。该研究旨在评估这种光动力疗法治疗四肢、颈部和躯干部位光化性角化病的有效性和安全性。\n随着最后一名受试者完成研究流程，这项重要的三期临床试验正式结束患者招募和治疗阶段。这标志着Biofrontera Inc在推进其Ameluz®产品用于治疗特定部位光化性角化病方面取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BFRIW","BFRI","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":9,"code":"91000000","status":"200"}]}}